Over the last few years, the pharma industry has been restructuring its research and development activities, facing constant pressure from patent expiry, generic competition, and declining revenues. Contract research organisations (CROs) are responding to the changing pharma landscape by constantly improving their service offerings. However, many CROs are more focused on quantity rather than quality as there has been a heightened demand for productivity and cost-effectiveness. “At GreenLight Clinical, we focus on delivering high-quality work and, at the same time, help clients minimise their expenses,” states Dr. Sasi Suda, president and CEO of GreenLight Clinical. As a true global full-service CRO, the company prides itself on servicing every phase of an investigation or study, from pre-clinical research all the way to first-in-human studies, late phase clinical trials and product registration.
“We consolidate our services in-house, with minimal reliance on third-party vendors,” says Suda. The benefit of having our own dedicated teams across our core service offerings ensures that clients always obtain quicker responses to their questions and detailed communication at each step of their clinical programs. GreenLight Clinical streamlines its practices using innovative, real-world data and cutting-edge analytics, supported by the first-in-class IT systems and personnel. The goal is to collaborate with clients to advance the development of safe, effective medical treatments that improve and save lives of patients.
Since its establishment in 2006, GreenLight Clinical has successfully conducted over 120 clinical trials, with many of those being industry-funded commercial studies. This substantial amount of experience in conducting clinical trials allows GreenLight Clinical to establish a highly effective working relationship with an extensive network of health professionals across a broad range of indications, from ophthalmology, dermatology, cardiovascular diseases, and various types of cancers among many others. Consequently, the company is capable of always matching clients with the right investigators to ensure that every trial meets its milestones, and potentially life-saving therapeutics are delivered to the patient as soon as they are available.
GreenLight Clinical has a strong focus on providing a full suite of clinical trial, drug safety, pharmacovigilance, biostatistics, and program development services to sponsors. “We deal extensively with small to medium biotech and pharma companies that often have large development teams for product design and manufacture, but require assistance in terms of study design, regulatory and medical affairs, and product registration,” says Suda. GreenLight Clinical recently assisted a biotech firm from South East Asia with a promising oncology drug to design a far more effective Phase II study than what the Sponsor had previously proposed. Through the course of their Phase I study, a significant change to the product was developed in the lab, and rather than go back to an entirely new Phase I, GreenLight Clinical identified the potential for a bridging study that could enable the on-time progression of the clinical program. This helped keep costs under control, while also meeting the sponsor’s deadlines. Enabling this study to progress has opened up significant opportunities for out-licensing, which could ultimately allow more patients to access a new treatment for intractable diseases.
Moving forward, GreenLight Clinical is developing a global, central pathology lab, which will be completed in Q1 of 2019. Apart from the central lab, the company is keen on expanding its services to drug and device development; while increasing efforts to recruit top clinical research talent in an effort to perfect and streamline services. GreenLight Clinical’s vision is to become a global CRO of choice, and assist small and medium-sized biotech/pharma companies to access a suite of high-quality services only offered by the biggest CROs that may have previously been out of reach, at a cost-effective price point.
Click here to read the full article and latest issue of Pharma Tech Outlook magazine.